Exhibit No.
|
Description
|
|
101
|
Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Consolidated Interim Statements of Financial Position, (ii) Consolidated Interim Statements of Profit or Loss, (iii) Consolidated Interim Statements of Changes in Equity; (iv) Consolidated Interim Statements of Cash Flows, and (v) Notes to Interim Consolidated Financial Statements
|
Date: August 31, 2021 |
|
EVOGENE LTD.
(Registrant) By: /s/ Dorit Kreiner Dorit Kreiner Chief Financial Officer |
Page
|
|
F-2
|
|
F-3
|
|
F-4
|
|
F-5 - F-6
|
|
F-7 - F-15
|
June 30,
|
December 31,
|
|||||||
2021
|
2020
|
|||||||
Unaudited
|
Audited
|
|||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
42,755
|
$
|
46,229
|
||||
Marketable securities
|
20,609
|
-
|
||||||
Short-term bank deposits
|
2,000
|
2,000
|
||||||
Trade receivables
|
208
|
222
|
||||||
Other receivables and prepaid expenses
|
2,295
|
3,372
|
||||||
67,867
|
51,823
|
|||||||
LONG-TERM ASSETS:
|
||||||||
Long-term deposits
|
12
|
9
|
||||||
Right-of-use-assets
|
1,876
|
1,872
|
||||||
Property, plant and equipment, net
|
2,105
|
2,072
|
||||||
Intangible assets, net
|
15,677
|
16,139
|
||||||
19,670
|
20,092
|
|||||||
$
|
87,537
|
$
|
71,915
|
|||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$
|
1,203
|
$
|
863
|
||||
Employees and payroll accruals
|
2,217
|
2,535
|
||||||
Lease liability
|
785
|
777
|
||||||
Liabilities in respect of government grants
|
144
|
72
|
||||||
Pre-funded warrants
|
-
|
4,144
|
||||||
Deferred revenues and other advances
|
26
|
47
|
||||||
Other payables
|
951
|
1,238
|
||||||
5,326
|
9,676
|
|||||||
LONG-TERM LIABILITIES:
|
||||||||
Lease liability
|
1,602
|
1,663
|
||||||
Liabilities in respect of government grants
|
3,966
|
3,694
|
||||||
5,568
|
5,357
|
|||||||
SHAREHOLDERS' EQUITY:
|
||||||||
Ordinary Shares of NIS 0.02 par value:
Authorized – 150,000,000 shares; Issued and outstanding – 40,621,124 as of June 30, 2021 and 35,600,088 as of December 31, 2020
|
231
|
200
|
||||||
Share premium and other capital reserve
|
258,258
|
225,121
|
||||||
Accumulated deficit
|
(192,088
|
)
|
(179,276
|
)
|
||||
Equity attributable to equity holders of the Company
|
66,401
|
46,045
|
||||||
Non-controlling interests
|
10,242
|
10,837
|
||||||
Total equity
|
76,643
|
56,882
|
||||||
$
|
87,537
|
$
|
71,915
|
Six months ended
June 30,
|
||||||||
2021
|
2020
|
|||||||
Unaudited
|
||||||||
Revenues
|
$
|
468
|
$
|
373
|
||||
Cost of revenues
|
399
|
153
|
||||||
Gross profit
|
69
|
220
|
||||||
Operating expenses:
|
||||||||
Research and development, net
|
9,283
|
8,478
|
||||||
Business development
|
1,242
|
1,438
|
||||||
General and administrative
|
3,249
|
2,388
|
||||||
Total operating expenses
|
13,774
|
12,304
|
||||||
Operating loss
|
(13,705
|
)
|
(12,084
|
)
|
||||
Financing income
|
617
|
643
|
||||||
Financing expenses
|
(919
|
)
|
(584
|
)
|
||||
Financing income (expense), net
|
(302
|
)
|
59
|
|||||
Loss before taxes on income
|
(14,007
|
)
|
(12,025
|
)
|
||||
Taxes on income
|
11
|
7
|
||||||
Loss
|
$
|
(14,018
|
)
|
$
|
(12,032
|
)
|
||
Attributable to:
|
||||||||
Equity holders of the Company
|
$
|
(12,812
|
)
|
$
|
(10,468
|
)
|
||
Non-controlling interests
|
(1,206
|
)
|
(1,564
|
)
|
||||
$
|
(14,018
|
)
|
$
|
(12,032
|
)
|
|||
Basic and diluted loss per share, attributable to equity holders of the Company
|
$
|
(0.32
|
)
|
$
|
(0.41
|
)
|
||
Weighted average number of Shares used in computing basic and diluted loss per share
|
39,778,174
|
25,754,297
|
Attributable to equity holders of the Company
|
||||||||||||||||||||||||
Share
capital
|
Share premium and other capital reserves
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total equity
|
|||||||||||||||||||
Unaudited
|
||||||||||||||||||||||||
Balance as of January 1, 2020
|
$
|
142
|
$
|
205,904
|
$
|
(155,902
|
)
|
$
|
50,144
|
$
|
10,073
|
$
|
60,217
|
|||||||||||
Loss
|
-
|
-
|
(10,468
|
)
|
(10,468
|
)
|
(1,564
|
)
|
(12,032
|
)
|
||||||||||||||
Benefit to non-controlling interests regarding share-based compensation
|
-
|
(6
|
)
|
-
|
(6
|
)
|
6
|
-
|
||||||||||||||||
Share-based compensation
|
92
|
92
|
2,697
|
2,789
|
||||||||||||||||||||
Balance as of June 30, 2020
|
$
|
142
|
$
|
205,990
|
$
|
(166,370
|
)
|
$
|
39,762
|
$
|
11,212
|
$
|
50,974
|
Attributable to equity holders of the Company
|
||||||||||||||||||||||||
Share
capital
|
Share premium and other capital reserves
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total equity
|
|||||||||||||||||||
Unaudited
|
||||||||||||||||||||||||
Balance as of January 1, 2021
|
$
|
200
|
$
|
225,121
|
$
|
(179,276
|
)
|
$
|
46,045
|
$
|
10,837
|
$
|
56,882
|
|||||||||||
Loss
|
-
|
-
|
(12,812
|
)
|
(12,812
|
)
|
(1,206
|
)
|
(14,018
|
)
|
||||||||||||||
Issuance of Ordinary Shares |
24 |
27,898 |
- |
27,922 |
- |
27,922 |
||||||||||||||||||
Exercise of pre-funded warrants |
6 |
4,359 |
- |
4,365 |
- |
4,365 |
||||||||||||||||||
Forfeiture of non-controlling interests regarding share-based compensation
|
- |
186 |
- |
186 |
(186 |
) |
- |
|||||||||||||||||
Benefit to non-controlling interests regarding share-based compensation
|
-
|
(13
|
)
|
-
|
(13
|
)
|
13
|
-
|
||||||||||||||||
Exercise of options |
1 |
402 |
- |
403 |
- |
403 |
||||||||||||||||||
Share-based compensation
|
- |
305
|
- |
305
|
784
|
1,089
|
||||||||||||||||||
Balance as of June 30, 2021
|
$
|
231
|
$ |
258,258
|
$
|
(192,088
|
)
|
$ |
66,401
|
$
|
10,242
|
$ |
76,643
|
Six months ended
June 30,
|
||||||||
2021
|
2020
|
|||||||
Unaudited
|
||||||||
Cash flows from operating activities
|
||||||||
Loss
|
$
|
(14,018
|
)
|
$
|
(12,032
|
)
|
||
Adjustments to reconcile loss to net cash used in operating activities:
|
||||||||
Adjustments to the profit or loss items:
|
||||||||
Depreciation
|
672
|
916
|
||||||
Amortization of intangible assets
|
462
|
465
|
||||||
Share-based compensation
|
1,089
|
2,789
|
||||||
Pre-funded warrants issuance expenses
|
212
|
-
|
||||||
Net financing income
|
(7
|
)
|
(66
|
)
|
||||
Taxes on income
|
11
|
7
|
||||||
2,439
|
4,111
|
|||||||
Changes in asset and liability items:
|
||||||||
Decrease in trade receivables
|
14
|
13
|
||||||
Decrease in other receivables and prepaid expenses
|
1,010
|
390
|
||||||
Increase in long-term deposits
|
(3
|
)
|
-
|
|||||
Increase (decrease) in trade payables
|
355
|
(234
|
)
|
|||||
Decrease in employees and payroll accruals
|
(318
|
)
|
(483
|
)
|
||||
Decrease in other payables
|
(278
|
)
|
(229
|
)
|
||||
Increase (decrease) in deferred revenues and other advances
|
(21
|
)
|
172
|
|||||
759
|
(371
|
)
|
||||||
Cash received (paid) during the period for:
|
||||||||
Interest received
|
145
|
166
|
||||||
Interest paid
|
(138
|
)
|
(118
|
)
|
||||
Taxes paid
|
(11
|
)
|
(7
|
)
|
||||
Net cash used in operating activities
|
$
|
(10,824
|
)
|
$
|
(8,251
|
)
|
Six months ended
June 30,
|
||||||||
2021
|
2020
|
|||||||
Unaudited
|
||||||||
Cash flows from investing activities:
|
||||||||
Purchase of property, plant and equipment
|
(407
|
)
|
(415
|
)
|
||||
Proceeds from sale of marketable securities
|
406
|
2,097
|
||||||
Purchase of marketable securities
|
(20,990
|
)
|
-
|
|||||
Proceeds from bank deposits, net
|
-
|
3,000
|
||||||
Net cash provided by (used in) investing activities
|
$
|
(20,991
|
)
|
$
|
4,682
|
|||
Cash flows from financing activities:
|
||||||||
Proceeds from issuance of Ordinary Shares, net of issuance expenses
|
27,922
|
-
|
||||||
Proceeds from exercise of options
|
460
|
-
|
||||||
Repayment of lease liability
|
(316
|
)
|
(329
|
)
|
||||
Proceeds from government grants
|
380
|
175
|
||||||
Repayment of government grants
|
(20
|
)
|
(11
|
)
|
||||
Net cash provided by (used in) financing activities
|
28,426
|
(165
|
)
|
|||||
Exchange rate differences - cash and cash equivalent balances
|
(85
|
)
|
60
|
|||||
Decrease in cash and cash equivalents
|
(3,474
|
)
|
(3,674
|
)
|
||||
Cash and cash equivalents, at the beginning of the period
|
46,229
|
34,748
|
||||||
Cash and cash equivalents, at the end of the period
|
$
|
42,755
|
$
|
31,074
|
||||
Significant non-cash activities
|
||||||||
Acquisition of property, plant and equipment
|
$
|
42
|
$
|
117
|
||||
Increase of right-of-use asset recognized with corresponding lease liability
|
$
|
317
|
$
|
-
|
U.S. dollars in thousands
a. |
Evogene Ltd. (“Evogene” and together with its subsidiaries, the “Company”) was founded on October 10, 1999, as Agro Leads Ltd., a division of Compugen Ltd. In 2002, the Company was spun-off as an independent corporation under the laws of the State of Israel, and changed its name to Evogene Ltd.
|
b. |
The Company principally derives its revenues from collaboration arrangements, see Note 3. For revenues from major customers see Note 7d.
|
|
c. |
The Company has the following subsidiaries: Casterra Ag Ltd. (formerly Evofuel Ltd.), Evogene Inc., Biomica Ltd., AgPlenus Ltd., AgPlenus Inc., Lavie Bio Ltd., Lavie Bio Inc., Lavie Bio Tech Inc., Taxon Biosciences, Inc. and Canonic Ltd.
|
d. |
On August 6, 2019, Corteva Inc. (“Corteva”) invested in the Company's agriculture biologicals subsidiary, Lavie Bio Ltd., which included a cash investment of $10,000 and the contribution of all shares of Corteva’s wholly owned subsidiary Taxon Biosciences, Inc. for 27.84% of Lavie Bio Ltd.'s shares. As part of the foregoing transaction, the parties entered into a commercial arrangement, including with respect to the commercialization by Corteva of Lavie Bio Ltd.’s products, mainly in corn and soybean.
|
e. |
On September 2, 2020, the Company issued 5,882,353 ordinary shares in a registered direct offering, for gross proceeds of $10,000 and on November 2, 2020, the Company issued 3,920,000 ordinary shares and 883,534 pre-funded warrants in a second registered direct offering, for gross proceeds of $12,000. On January 4, 2021, all 883,534 pre-funded warrants were exercised into 883,534 of the Company's ordinary shares at an exercise price of $0.01 per pre-funded warrant for a total amount of $9.
|
f. |
On January 14, 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the “January 2021 Sales Agreement”). In January and February 2021, pursuant to the January 2021 Sales Agreement, in an “at the market” (“ATM”) offering, the Company issued an aggregate of 3,803,594 ordinary shares with a weighted average selling price of $7.36 per share, resulting in gross proceeds of $28,000.
|
g. |
The Company’s subsidiaries and divisions are split into three operating segments: (1) Agriculture - Evogene seed traits division, Lavie Bio Ltd. and Ag Plenus Ltd.; (2) Human – Biomica Ltd. and Canonic Ltd.; and (3) Industrial – Casterra Ag Ltd. (see also Note 7).
|
h. |
The duration, scope and effects of the ongoing COVID-19 pandemic, government and other third-party responses to it, and the related macroeconomic effects, and the extent of its impact on the Company’s operational and financial performance will depend on certain developments. The Company considered the impact of COVID-19 on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the period ended June 30, 2021. As events continue to evolve and additional information becomes available, the Company’s estimates and assumptions may change in future periods.
|
|
a. |
Basis of preparation of the interim consolidated financial statements:
|
The significant accounting policies applied in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the 2020 annual consolidated financial statements.
b. |
Amendment to IAS 16, "Property, Plant and Equipment": |
c. |
Amendment to IAS 37, "Provisions, Contingent Liabilities and Contingent Assets": |
In May 2020, the IASB issued an amendment to IAS 37, regarding which costs a company should include when assessing whether a contract is onerous ("the IAS 37 Amendment"). According to the IAS 37 Amendment, costs of fulfilling a contract include both the incremental costs (for example, raw materials and direct labor) and an allocation of other costs that relate directly to fulfilling a contract (for example, depreciation of an item of property, plant and equipment used in fulfilling the contract).
d. |
Annual improvements to IFRSs 2018-2020:
|
NOTE 3: - |
COLLABORATION AND RESEARCH AGREEMENTS-
|
June 30,
2021
|
December 31, 2020
|
|||||||
Unaudited
|
Audited
|
|||||||
Financial assets measured at fair value through profit or loss:
|
||||||||
Participation certificates in trust funds – Level 1
|
$
|
13,574
|
$
|
-
|
||||
Corporate bonds and government treasury notes – Level 2
|
7,035
|
-
|
||||||
$
|
20,609
|
$
|
-
|
June 30,
2021
|
December 31, 2020
|
|||||||
Unaudited
|
Audited
|
|||||||
Balance at January 1,
|
$
|
3,766
|
$
|
3,362
|
||||
Grants received
|
380
|
320
|
||||||
Royalties paid
|
(20
|
)
|
(22
|
)
|
||||
Amounts recorded in profit or loss
|
(16
|
)
|
106
|
|||||
$
|
4,110
|
$
|
3,766
|
a. |
Expenses recognized in the financial statements:
|
Six months ended
June 30,
|
||||||||
2021
|
2020
|
|||||||
Unaudited
|
||||||||
Share-based compensation - Attributable to equity holders of the Company
|
$
|
234
|
$
|
68
|
||||
Share-based compensation - Attributable to non-controlling interests
|
855
|
2,721
|
||||||
|
$ | 1,089 |
|
$ | 2,789 |
b. |
Evogene Ltd. share-based payment plan for employees, directors and consultants:
|
During the six months ended June 30, 2021 and 2020, the board of directors of Evogene Ltd. approved to grant its employees, directors and consultants an aggregate of 217,500 and 790,000 options, respectively. The fair value of the options determined at their grant date using the binomial model was approximately $356 and $184, respectively.
c. |
Evogene Ltd. share options activity:
|
2021
|
2020
|
|||||||||||||||
Number of options
|
Weighted average exercise prices ($)
|
Number of options
|
Weighted average exercise prices ($)
|
|||||||||||||
Outstanding on January 1,
|
4,030,702
|
6.24
|
4,335,017
|
7.08
|
||||||||||||
Granted
|
217,500
|
6.27
|
790,000
|
1.10
|
||||||||||||
Exercised
|
(136,383
|
)
|
2.96
|
-
|
-
|
|||||||||||
Forfeited
|
(360,980
|
)
|
10.50
|
(807,468
|
)
|
6.95
|
||||||||||
Outstanding on June 30,
|
3,750,839
|
6.42
|
4,317,549
|
5.99
|
||||||||||||
Exercisable at June 30,
|
2,417,326
|
7.67
|
2,511,019
|
8.74
|
|
d. |
The Company's subsidiaries maintain share option and incentive plans with similar terms and conditions. During the six months ended June 30, 2021 and 2020, the Company's subsidiaries approved to grant their employees, directors and consultants 431,851 and 775,848 options, respectively. The fair value of the options determined at their grant date using the binomial model was approximately $1,311 and $4,068, respectively. The fair value was estimated using the binomial model.
|
|
U.S. dollars in thousands
NOTE 6: - SHARE- BASED COMPENSATION (Cont.)
2021
|
2020
|
|||||||||||||||
Number of options*
|
Weighted average exercise prices* ($)
|
Number of options
|
Weighted average exercise prices ($)
|
|||||||||||||
Outstanding on January 1,
|
1,798,780
|
0.90
|
460,038
|
0.13
|
||||||||||||
Granted
|
431,851
|
4.71
|
775,848
|
1.94
|
||||||||||||
Exercised
|
-
|
-
|
-
|
-
|
||||||||||||
Forfeited
|
(16,485
|
)
|
0.20
|
(40,484
|
)
|
0.20
|
||||||||||
Outstanding on June 30,
|
2,214,146
|
1.65
|
1,195,402
|
1.31
|
||||||||||||
Exercisable at June 30,
|
1,007,821
|
0.63
|
502,257
|
0.17
|
*) Retroactively reflect the 1:10 ordinary share split implemented on June 8, 2021, in Canonic Ltd.
e. |
The total compensation cost related to all of the Company's equity-based awards, recognized during the presented periods was comprised as follows:
|
Six months ended June 30,
|
||||||||
2021
|
2020
|
|||||||
Unaudited
|
||||||||
Research and development, net |
$
|
532
|
$
|
1,404
|
||||
Business development |
269
|
897
|
||||||
General and administrative |
288 | 488 | ||||||
$
|
1,089
|
$
|
2,789
|
NOTE 7: - OPERATING SEGMENTS
a. |
General:
|
Agriculture segment
|
-
|
Develops seed traits, ag-chemical products, and ag-biological products to improve plant performance.
|
Industry segment
|
-
|
Develops improved castor bean seeds to serve as a feedstock source for other industrial uses.
|
Human segment
|
-
|
Discovery and development of human microbiome-based therapeutics and cannabis activity.
|
Unallocated
|
-
|
Other corporate expenses and general development of enabling technologies for optimization.
|
b. |
The following table presents the Company’s revenues and operating loss by segments:
|
Agriculture
|
Industry
|
Human
|
Unallocated
|
Total
|
||||||||||||||||
Unaudited
|
||||||||||||||||||||
For the six months ended June 30, 2021
|
||||||||||||||||||||
Revenues
|
$
|
396
|
$
|
-
|
$
|
25
|
$
|
47
|
$
|
468
|
||||||||||
Operating loss
|
$
|
(5,144
|
)
|
$
|
(73
|
)
|
$
|
(3,257
|
)
|
$
|
(5,231
|
)
|
$
|
(13,705
|
)
|
|||||
Net financing expense
|
$
|
(302
|
)
|
|||||||||||||||||
Loss before taxes on income
|
$
|
(14,007
|
)
|
c. |
The following table presents the Company’s revenues and operating loss by segments: |
Agriculture
|
Industry
|
Human
|
Unallocated
|
Total
|
||||||||||||||||
Unaudited
|
||||||||||||||||||||
For the six months ended June 30, 2020
|
||||||||||||||||||||
Revenues
|
$
|
354
|
$
|
-
|
$
|
-
|
$
|
19
|
$
|
373
|
||||||||||
Operating loss
|
$
|
(4,392
|
)
|
$
|
(147
|
)
|
$
|
(1,861
|
)
|
$
|
(5,684
|
)
|
$
|
(12,084
|
)
|
|||||
Net financing income
|
$
|
59
|
||||||||||||||||||
Loss before taxes on income
|
$
|
(12,025
|
)
|
d. |
Major customers:
|
Six months ended
June 30,
|
||||||||
2021
|
2020
|
|||||||
Unaudited
|
||||||||
Customer A
|
-
|
12
|
%
|
|||||
Customer B (subsidiary shareholder)
|
34
|
%
|
67
|
%
|
||||
Customer C
|
40
|
%
|
-
|
|||||
Customer D
|
*)-
|
|
12
|
%
|
||||
Customer E
|
13
|
%
|
-
|
June 30, 2021
|
December 31, 2020
|
|||||||
Unaudited
|
Audited
|
|||||||
United States
|
89
|
%
|
82
|
%
|
||||
Israel
|
11
|
%
|
18
|
%
|
||||
100
|
%
|
100
|
%
|
Six Months Ended June 30,
|
||||||||
|
2021
|
2020
|
||||||
|
(U.S. dollars, in thousands)
|
|||||||
Net cash used in operating activities
|
$
|
(10,824
|
)
|
$
|
(8,251
|
)
|
||
Net cash provided (used in) by investing activities
|
(20,991
|
)
|
4,682
|
|||||
Net cash provided by (used in) financing activities
|
28,426
|
(165
|
)
|
|||||
Exchange rate differences - cash and cash equivalents
|
(85
|
)
|
60
|
|||||
Decrease in cash and cash equivalents
|
$
|
(3,474
|
)
|
$
|
(3,674
|
)
|